Resumen
Background: Evidence of efficacy and safety of digital ecosystems in Latin America is scarce, which has limited their
implementation. The objective of this study is to evaluate the safety and efficacy of the use of a digital ecosystem
(Zutrics) in people with Type 2 Diabetes (PwT2D) treated with insulin.
Methods: Analytical observational prospective cohort study in PwT2D, treated with insulin and oral or injectable
antidiabetics, with HbA1c >8%, and followed up with a digital ecosystem (Zutrics). HbA1c and derived time in range
(TIRd 70-180 mg/dL) were evaluated at baseline and at 3-month follow-up. Additionally, hypoglycemia events were
evaluated during the follow-up.
Results: We analyzed 69 patients (age 62 ± 12.5 years, 56.6% female), 45.1% had chronic kidney disease (CKD) and
25.4% coronary artery disease. About 45.1% were on multiple dose insulin treatment. Median HbA1c levels decreased
from a baseline value of 9.1% (interquartile range, IQR 7.5-11.4) to 7.0% (IQR 6.3-8.08) at 3-month follow-up (P = .044).
The median of HbA1c changes over time was −1.3% (IQR −0.13, −4.2). The mean TIRd of 70 to 180 mg/dL increased
from 74% at baseline to 76.1% at the end of follow-up. The TBRd of <70 mg/dL did not change significantly, going from
0.5% at baseline to 0.94% The incidence density of hypoglycemia episodes was 0.009 events/patient-day during the
follow-up. About 95.6% of patients met the goal of TBRd <70 mg/dL less than 4%
Conclusion: This study suggests that the use of a digital ecosystem in the follow-up of PwT2D allows better glycemic
control without increasing the risk of hypoglycemia.
implementation. The objective of this study is to evaluate the safety and efficacy of the use of a digital ecosystem
(Zutrics) in people with Type 2 Diabetes (PwT2D) treated with insulin.
Methods: Analytical observational prospective cohort study in PwT2D, treated with insulin and oral or injectable
antidiabetics, with HbA1c >8%, and followed up with a digital ecosystem (Zutrics). HbA1c and derived time in range
(TIRd 70-180 mg/dL) were evaluated at baseline and at 3-month follow-up. Additionally, hypoglycemia events were
evaluated during the follow-up.
Results: We analyzed 69 patients (age 62 ± 12.5 years, 56.6% female), 45.1% had chronic kidney disease (CKD) and
25.4% coronary artery disease. About 45.1% were on multiple dose insulin treatment. Median HbA1c levels decreased
from a baseline value of 9.1% (interquartile range, IQR 7.5-11.4) to 7.0% (IQR 6.3-8.08) at 3-month follow-up (P = .044).
The median of HbA1c changes over time was −1.3% (IQR −0.13, −4.2). The mean TIRd of 70 to 180 mg/dL increased
from 74% at baseline to 76.1% at the end of follow-up. The TBRd of <70 mg/dL did not change significantly, going from
0.5% at baseline to 0.94% The incidence density of hypoglycemia episodes was 0.009 events/patient-day during the
follow-up. About 95.6% of patients met the goal of TBRd <70 mg/dL less than 4%
Conclusion: This study suggests that the use of a digital ecosystem in the follow-up of PwT2D allows better glycemic
control without increasing the risk of hypoglycemia.
| Idioma original | Inglés |
|---|---|
| Número de páginas | 7 |
| Publicación | Clinical Medicine Insights: Endocrinology and Diabetes |
| Volumen | 18 |
| N.º | 1 |
| DOI | |
| Estado | Publicada - 01 ene. 2025 |
Palabras clave
- telehealth, digital ecosystem, type 2 diabetes, time in range